Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
MIRA Pharmaceuticals Inc. is a clinical-stage biotech focused on developing novel neuroscience therapies. Its key products include Ketamir-2, an oral ketamine analog for neuropathic pain and depression, and MIRA-55, a cannabinoid-based compound targeting neuroinflammation and cognitive decline. The company operates in North America, emphasizing safety, efficacy, and regulatory compliance to address unmet medical needs in neuropsychiatric and neurological disorders.
This description was generated via AI from an annual report. Updated about 1 year ago.